Shares of AnaptysBio Inc. remained flat in premarket trading Thursday after plunging over 32% in the prior session, marking ...

AnaptysBio has reported that the ARISE-AD trial of its investigational B and T lymphocyte attenuator (BTLA) agonist, ANB032, ...

Fintel reports that on December 11, 2024, HC Wainwright & Co. downgraded their outlook for AnaptysBio (NasdaqGS:ANAB) from ...

AnaptysBio, Inc. (NASDAQ:ANAB) announced that investigational ANB032, a BTLA agonist, did not meet the primary and secondary ...

TD Cowen analyst Joseph Thome maintained a Buy rating on AnaptysBio (ANAB – Research Report) today. The company’s shares opened today at ...

H.C. Wainwright analyst Emily Bodnar downgraded AnaptysBio (ANAB) to Neutral from Buy with a $19 price target Pick the best stocks and maximize ...

Q32 Bio delivered a "messy" update for its eczema and alopecia treatment, leading the biotech stock to collapse to a record ...

San Diego, USA-based biotech AnaptysBio today announced that investigational ANB032, a BTLA agonist, did not meet the primary ...

AnaptysBio is dropping its atopic dermatitis (AD) drug candidate after the compound failed to reduce eczema area and itch ...

The clinical-stage biotechnology company said its investigational drug ANB032 didn't meet either primary or secondary endpoints in its 201-patient Arise-AD trial as a therapy for atopic dermatitis, ...

AnaptysBio will end the development of its experimental drug to treat eczema as the treatment failed to meet the goals of a ...